Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Postdoc fellow– Bioinformatics & Executable Modelling for Rare Disease Digital Twins

We are looking for a motivated and talented postdoctoral-level researcher with experience in executable modelling to join a cutting-edge project developing Digital Twins for rare diseases. This is a unique opportunity to work at the intersection of systems biology, AI, and translational research, and to contribute to open science through the Chan Zuckerberg Initiative.

Your group
Petsalaki Group, in collaboration with Open Targets and BioModels teams.

How Can UK Tech & Life Sciences Companies Manage Tariffs Exposure

With the recent wave of US tariffs, UK businesses trading internationally face mounting cost pressures. For tech and life sciences companies, especially those sourcing physical goods from China and exporting to the US, these changes could significantly impact profitability and competitiveness.

Join us for an exclusive webinar hosted by Frazier & Deeter where our international tax and trade experts will explore how UK companies can manage tariff exposure

Speakers Include:

CN Bio Introduces Cross-species DILI Services to Enhance in Vitro to in Vivo Extrapolation During Preclinical Drug Development

  • Extends capabilities of industry-leading PhysioMimix DILI assay for comparative studies between animal species and human
  • Generates deeper insights into inter-species differences to de-risk development pipelines and minimize animal testing

Fewer meetings, faster teams and bolder outcomes – get out of ‘collabureaucracy’ and deliver your strategy!

Your strategy is ambitious. Your people are brilliant. But progress is slow. Why? Because your teams are overwhelmed with collaboration: meetings that don’t move things forward, bloated decision-making processes and a web of information and messages.

Most companies (even new ones!) are still running on industrial-era collaboration habits where meetings are the default modality, overwhelm is normal and progress requires too many people in too many conversations.

In the knowledge era, collaboration needs a new operating system - one with less friction and more flow.

Cambridge Network Connect, July 2025

Join some of the Cambridge Network team and fellow members for an afternoon of networking over tea, cakes and fruit at Cambridge Network Connect (previously known as Making the Most of Membership).  If you want to meet like-minded companies and some new people, come and join us for a couple of hours. We’d love to meet you too. No presentations this time (OK, welcomes and introductions from our CEO, hosts and sponsors)!

Event timings are:

Further growth for Boyds’ specialist Regulatory Operations team

Global drug development consultancy Boyds has announced the appointment of Lisa Allenby as Associate Director, Regulatory Operations.

Lisa has more than 25 years’ experience in regulatory operations, having previously worked at DLRC Regulatory Consultancy and pharmaceutical company Mylan. She has extensive experience of managing major filings across the globe, as well as leading cross-functional meetings representing regulatory operations in the submissions management process.

Microbiotica announces the appointment of Dr Robert Tansley as Chief Medical Officer

Cambridge, UK – 10 June 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.

Dr Tansley steps into the role at a key development stage for Microbiotica with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis) with data read-outs anticipated this year.

Subscribe to